TrialInternational journal of clinical oncology2024

Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study.

Kaname Nosaki et al.PubMed ↗Publisher ↗

No numbers read from the abstract.